Search results
Results from the WOW.Com Content Network
The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. AstraZeneca bets on new cancer treatments with $2 billion Fusion ...
Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Even if it's not a huge purchase, we think it was good to see that Steven Gannon, the Independent Director of Fusion... Insider Buying: The Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Independent ...
J. Michael Pearson (born 1959) is a Canadian American [1] pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International [2] [3] after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.
The United States Federal Drug Administration approves Vertex Pharmaceuticals' new Journavx drug, a non-opioid analgesic used to treat acute pain and potentially eliminate the risks of opioid addiction and overdose. Politics and elections
That same month, the firm also announced the acquisition of Fusion Pharmaceuticals Inc for $2 billion in cash. [ 100 ] In July 2024, National Institute for Health and Care Excellence (Nice) blocked the National Health Service (NHS) from providing Enhertu , an innovative treatment for advanced HER2-low breast cancer, due to AstraZeneca and ...
For premium support please call: 800-290-4726 more ways to reach us
Ariad's and Takeda's brigatinib (also an inhibitor of mutated EGFR) was the latest second-generation inhibitor and was approved in April 2017 by the US FDA for ALK-positive NSCLC. [14] It is very similar to alectinib in efficacy, while being active against some resistant mutations such as the common G1202R mutation that provides resistance to ...